Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

87.2 EUR
-3.6 (-3.96%)
Last: 12/9/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ADN1. ADN1 was compared to 77 industry peers in the IT Services industry. ADN1 has an average financial health and profitability rating. ADN1 is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year ADN1 was profitable.
In the past year ADN1 had a positive cash flow from operations.
Each year in the past 5 years ADN1 has been profitable.
In the past 5 years ADN1 always reported a positive cash flow from operatings.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

With a Return On Assets value of 2.45%, ADN1 perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
ADN1 has a Return On Equity of 10.90%. This is comparable to the rest of the industry: ADN1 outperforms 50.65% of its industry peers.
The Return On Invested Capital of ADN1 (5.23%) is worse than 62.34% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ADN1 is significantly below the industry average of 26.50%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

ADN1 has a worse Profit Margin (0.99%) than 62.34% of its industry peers.
ADN1's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 2.96%, ADN1 is doing worse than 66.23% of the companies in the same industry.
In the last couple of years the Operating Margin of ADN1 has declined.
The Gross Margin of ADN1 (85.30%) is better than 77.92% of its industry peers.
In the last couple of years the Gross Margin of ADN1 has remained more or less at the same level.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

ADN1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ADN1 has been reduced compared to 1 year ago.
The number of shares outstanding for ADN1 has been increased compared to 5 years ago.
The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ADN1 has an Altman-Z score of 3.64. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
ADN1 has a Altman-Z score of 3.64. This is in the better half of the industry: ADN1 outperforms 76.62% of its industry peers.
ADN1 has a debt to FCF ratio of 7.88. This is a slightly negative value and a sign of low solvency as ADN1 would need 7.88 years to pay back of all of its debts.
ADN1's Debt to FCF ratio of 7.88 is on the low side compared to the rest of the industry. ADN1 is outperformed by 66.23% of its industry peers.
ADN1 has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
ADN1 has a Debt to Equity ratio of 1.60. This is in the lower half of the industry: ADN1 underperforms 75.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.64
ROIC/WACC0.95
WACC5.51%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

ADN1 has a Current Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1 has a Current ratio of 1.30. This is comparable to the rest of the industry: ADN1 outperforms 55.84% of its industry peers.
ADN1 has a Quick Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1 has a better Quick ratio (1.30) than 62.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

ADN1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 200.98%, which is quite impressive.
The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
The Revenue has grown by 12.60% in the past year. This is quite good.
ADN1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.60% yearly.
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

Based on estimates for the next years, ADN1 will show a very strong growth in Earnings Per Share. The EPS will grow by 39.75% on average per year.
Based on estimates for the next years, ADN1 will show a quite strong growth in Revenue. The Revenue will grow by 10.61% on average per year.
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 27.34, the valuation of ADN1 can be described as expensive.
ADN1's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of ADN1 to the average of the S&P500 Index (26.28), we can say ADN1 is valued inline with the index average.
With a Price/Forward Earnings ratio of 15.42, ADN1 is valued correctly.
The rest of the industry has a similar Price/Forward Earnings ratio as ADN1.
The average S&P500 Price/Forward Earnings ratio is at 23.52. ADN1 is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 27.34
Fwd PE 15.42
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ADN1 is valued a bit cheaper than the industry average as 68.83% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ADN1 is valued a bit cheaper than the industry average as 62.34% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.18
EV/EBITDA 6.71
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

ADN1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADN1's earnings are expected to grow with 63.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y76.08%
EPS Next 3Y63.28%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.82%, ADN1 is not a good candidate for dividend investing.
ADN1's Dividend Yield is comparable with the industry average which is at 3.76.
Compared to an average S&P500 Dividend Yield of 2.31, ADN1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.82%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

ADN1 pays out 31.75% of its income as dividend. This is a sustainable payout ratio.
ADN1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP31.75%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (12/9/2025, 7:00:00 PM)

87.2

-3.6 (-3.96%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-31 2026-03-31/amc
Inst Owners20.45%
Inst Owner ChangeN/A
Ins Owners50.28%
Ins Owner ChangeN/A
Market Cap569.42M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts81.54
Price Target126.63 (45.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.82%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.91%
PT rev (3m)-0.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.47%
EPS NY rev (3m)-12.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.41%
Valuation
Industry RankSector Rank
PE 27.34
Fwd PE 15.42
P/S 0.27
P/FCF 12.18
P/OCF 7.33
P/B 2.98
P/tB 11.24
EV/EBITDA 6.71
EPS(TTM)3.19
EY3.66%
EPS(NY)5.65
Fwd EY6.48%
FCF(TTM)7.16
FCFY8.21%
OCF(TTM)11.9
OCFY13.64%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.33
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.64
F-Score7
WACC5.51%
ROIC/WACC0.95
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year302.45%
EBIT Next 3Y80.25%
EBIT Next 5Y44.55%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


What is the valuation status of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the valuation of ADESSO SE based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 27.34 and the Price/Book (PB) ratio is 2.98.


Is the dividend of ADESSO SE sustainable?

The dividend rating of ADESSO SE (ADN1.DE) is 4 / 10 and the dividend payout ratio is 31.75%.